Uppsala, Sweden, 2015-03-05 08:14 CET (GLOBE NEWSWIRE) --
THIRD QUARTER November 1, 2014 – January 31, 2015
- Consolidated Net sales amounted to TSEK 482 (16)[1]
- Operating income amounted to TSEK -25,479 (-28,492)
- Net income after tax amounted to TSEK -27,713 (-30,436)
- Earnings per share amounted to SEK -0.30 (-0.37)
- Comprehensive income amounted to TSEK -27,713 (-30,436)
THE PERIOD May 1, 2014 – January 31, 2015
- Consolidated Net sales amounted to TSEK 2,034 (40)
- Operating income amounted to TSEK -79,975 (-62,851)
- Net income after tax amounted to TSEK -87,416 (-67,321)
- Earnings per share amounted to SEK -0.98 (-0.82)
- Comprehensive income amounted to TSEK -87,416 (-67,321)
- Preferential rights issue completed in December 2014
- Oasmia share moved from the Small Cap to the Mid Cap segment at NASDAQ Stockholm
EVENTS AFTER THE CLOSING DAY
- In February, Oasmia initiated a clinical Phase II study with Doxophos Vet for treatment of lymphoma in dogs
“The third quarter was eventful. Zoetis, the leading animal health company, has completed the acquisition of Abbott Animal Health including the distribution rights to Paccal Vet and Doxophos Vet. Since Zoetis has a much larger presence on the market in the USA and globally, we hope that this will be a fruitful collaboration and thus successful for Oasmia’s products. Zoetis together with Oasmia will be world-leading within veterinary oncology with this acquisition.”, said Julian Aleksov, CEO of Oasmia.
We have also increased our focus on the next product Docecal significantly. It strengthens the conditions for the long-term growth of the company. Docecal is a novel formulation of docetaxel (Taxotere). The market for this substance is about three times larger compared to the market for paclitaxel (Paclical).”
[1] The numbers in parentheses show the results from the corresponding period of the previous year
Anders Lundin, CFO
Tel: +46 70 209 63 00
E-post: anders.lundin@oasmia.com
